JP2023501347A5 - - Google Patents

Info

Publication number
JP2023501347A5
JP2023501347A5 JP2022526035A JP2022526035A JP2023501347A5 JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5 JP 2022526035 A JP2022526035 A JP 2022526035A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2023501347 A5 JP2023501347 A5 JP 2023501347A5
Authority
JP
Japan
Prior art keywords
sequence
antisense oligomer
fcεriβ
exon
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059682 external-priority patent/WO2021092562A1/en
Publication of JP2023501347A publication Critical patent/JP2023501347A/ja
Publication of JP2023501347A5 publication Critical patent/JP2023501347A5/ja
Pending legal-status Critical Current

Links

JP2022526035A 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ Pending JP2023501347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (2)

Publication Number Publication Date
JP2023501347A JP2023501347A (ja) 2023-01-18
JP2023501347A5 true JP2023501347A5 (cg-RX-API-DMAC10.html) 2023-11-16

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526035A Pending JP2023501347A (ja) 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ

Country Status (6)

Country Link
US (1) US12637677B2 (cg-RX-API-DMAC10.html)
EP (1) EP4054639A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023501347A (cg-RX-API-DMAC10.html)
CN (1) CN115335078A (cg-RX-API-DMAC10.html)
AU (1) AU2020378207A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021092562A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
JP2025531483A (ja) * 2022-09-28 2025-09-19 アタランタ セラピューティクス,インコーポレーテッド 神経炎症疾患の治療のための組成物及び方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989849A (en) 1991-05-09 1999-11-23 Temple University Of The Commonwealth System Of Higher Education Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
AU2005214287A1 (en) 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders
WO2005085443A2 (en) 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
ES2627917T3 (es) 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
EP2290088A1 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-menbrane-spanning proteins
WO2007028065A2 (en) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
ES2566553T3 (es) 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
EP3023496B1 (en) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Compounds which modulate interleukins 17 and 23 signaling activity
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
EP3174981B1 (en) 2014-07-31 2020-03-25 Association Institut de Myologie Treatment of amyotrophic lateral sclerosis
EP2985343A1 (en) 2014-08-11 2016-02-17 Karlsruher Institut für Technologie In vitro-co-culturesystem
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
WO2019200383A1 (en) * 2018-04-13 2019-10-17 Ohio State Innovation Foundation Reagents and methods for autism and comorbidities thereof
EP3844278A4 (en) 2018-08-27 2022-05-25 North Carolina State University TARGETING KIT WITH SPLICE-SWITCHING OLIGONUCLEOTIDES FOR INDUCING APOPTOSIS OF MASTS CELLS

Similar Documents

Publication Publication Date Title
US20200291407A1 (en) Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
AU2018318135B2 (en) Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
US8946183B2 (en) Compositions and methods for modulation of SMN2 splicing
JP2022523302A (ja) アッシャー症候群の処置のためのrna編集オリゴヌクレオチド
ES2600356T3 (es) Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
BR112020007881A2 (pt) Oligômeros anti-senso para o tratamento de condições e doenças baseadas no decaimento de rna mediado por nonsense
TW201210611A (en) Treatment of Nicotinamide Phosphoribosyltransferase (NAMPT) related diseases by inhibition of natural antisense transcript to NAMPT
JPH09510714A (ja) オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性
KR20080031164A (ko) SR 단백질의 결합의 방해에 의해 그리고 이차 RNA구조의 방해에 의한 pre-mRNA에서 엑손 인식의조절
JP2024537991A5 (cg-RX-API-DMAC10.html)
JP2019500347A5 (cg-RX-API-DMAC10.html)
TW201219569A (en) Treatment of Sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CA2785727A1 (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
TW201209163A (en) Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
Slavov et al. Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns
JP2021534799A5 (cg-RX-API-DMAC10.html)
JP2023542889A5 (cg-RX-API-DMAC10.html)
US20260035694A1 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
US12529057B2 (en) Therapeutics for Syngap haploinsufficiency
CN115103911A (zh) 修饰的异源核酸
JP2024524974A5 (cg-RX-API-DMAC10.html)
JPH09501057A (ja) 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節
JP2022546408A5 (cg-RX-API-DMAC10.html)
Soldà et al. In vivo RNA–RNA duplexes from human α3 and α5 nicotinic receptor subunit mRNAs